OUR MISSION
Crucible is on a mission to create cures for people with neurodegenerative diseases, including ALS and FTD, for which there remains an urgent need.
Our company is leading the way with RNA-targeting approaches aimed at halting, and potentially reversing, neurodegenerative diseases.
We are currently focused on the most common genetic form of Motor Neuron Disease (NMD; also known as Amyotrophic Lateral Sclerosis, ALS) and frontotemporal dementia (FTD).
Crucible Therapeutics was founded in 2023 to advance groundbreaking innovations in neuroscience, originating from the Sheffield Institute for Translational Neuroscience (SITraN) and the Division of Neuroscience at the University of Sheffield, U.K.
